One group of agents that target the kinase domain of EGFR, called tyrosine kinase inhibitors (TKIs), are clinically active and broadly applied in the treatments of cancers such as non-small-cell lung carcinoma (NSCLC) [4, 13, 15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.